Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169086 | 1.00 | TACR1 (0.47) | TACR1TAAR1ADRA2AADRA2CLMNA | |
| SCHEMBL28906870 | 0.83 | TAAR1 (0.45) | TAAR1ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL9449194 | 0.79 | ADRA2C (0.61) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL6743516 | 0.79 | ADRA2C (0.61) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL26923438 | 0.77 | TACR1 (0.50) | TACR1TAAR1ADRA2AADRA2CLMNA | |
| SCHEMBL13995085 | 0.77 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL6856102 | 0.77 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL5914545 | 0.77 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL28004002 | 0.77 | TACR1 (0.46) | TACR1TAAR1ADRA2AADRA2CLMNA | |
| SCHEMBL6743358 | 0.76 | THRB (0.46) | TAAR1ADRA2AADRA2CLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768659-B1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF ALPHA-(DIARYLMETHYL) ALKYL AMINES | PIRAMAL PHARMA LTD (IN) | 2023-07-19 | — | — | EP | disclosed |
| US-11279668-B2 | Asymmetric synthesis of alpha-(diarylmethyl) alkyl amines | PIRAMAL PHARMA LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| US-20210061752-A1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES | Piramal Enterprises Limited (IN) | 2021-03-04 | — | — | US | disclosed |
| EP-3768659-A1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF ALPHA-(DIARYLMETHYL) ALKYL AMINES | Piramal Pharma Limited (IN) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019180627-A1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES | Piramal Enterprises Limited (IN) | 2019-09-26 | — | — | WO | disclosed |
| US-7126028-B1 | Process for preparing chiral compounds | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2006-10-24 | — | — | US | disclosed |
| EP-1135349-A1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | UNIVERSITY OF DURHAM (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034210-A1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | UNIVERSITY OF DURHAM (GB) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061752-A1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES | SAT1, BET1, SRM | TACR1 2688/4885TAAR1 103/4885ADRA2A 451/4885 |
| US-11279668-B2 | Asymmetric synthesis of alpha-(diarylmethyl) alkyl amines | SAT1, SRM, SMS | TACR1 2246/4885TAAR1 73/4885ADRA2A 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.